IL155781A0 - Effective antitumor treatments - Google Patents

Effective antitumor treatments

Info

Publication number
IL155781A0
IL155781A0 IL15578101A IL15578101A IL155781A0 IL 155781 A0 IL155781 A0 IL 155781A0 IL 15578101 A IL15578101 A IL 15578101A IL 15578101 A IL15578101 A IL 15578101A IL 155781 A0 IL155781 A0 IL 155781A0
Authority
IL
Israel
Prior art keywords
effective antitumor
antitumor treatments
treatments
effective
tumour
Prior art date
Application number
IL15578101A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155781(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of IL155781A0 publication Critical patent/IL155781A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL15578101A 2000-11-06 2001-11-06 Effective antitumor treatments IL155781A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24623300P 2000-11-06 2000-11-06
US24809500P 2000-11-13 2000-11-13
US34598201P 2001-10-19 2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en) 2000-11-06 2001-11-06 Compositions for antitumour treatment containing ecteinascidin 743

Publications (1)

Publication Number Publication Date
IL155781A0 true IL155781A0 (en) 2003-12-23

Family

ID=27399908

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15578101A IL155781A0 (en) 2000-11-06 2001-11-06 Effective antitumor treatments

Country Status (25)

Country Link
US (3) US20040108086A1 (cs)
EP (1) EP1365808B1 (cs)
JP (2) JP4391083B2 (cs)
KR (1) KR100718946B1 (cs)
CN (1) CN100374162C (cs)
AT (1) ATE495793T1 (cs)
AU (2) AU2002212499B2 (cs)
BG (1) BG107843A (cs)
BR (1) BR0115162A (cs)
CA (1) CA2428160C (cs)
CY (1) CY1112361T1 (cs)
CZ (1) CZ20031327A3 (cs)
DE (1) DE60143911D1 (cs)
DK (1) DK1365808T3 (cs)
EA (1) EA005564B1 (cs)
HK (1) HK1060067A1 (cs)
HU (1) HUP0400648A3 (cs)
IL (1) IL155781A0 (cs)
MX (1) MXPA03003975A (cs)
NO (1) NO329981B1 (cs)
NZ (1) NZ525730A (cs)
PL (1) PL361389A1 (cs)
PT (1) PT1365808E (cs)
SK (1) SK287901B6 (cs)
WO (1) WO2002036135A2 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
ATE495793T1 (de) * 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
CA2583464A1 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
PT1827500E (pt) * 2004-10-26 2009-08-05 Pharma Mar Sa Doxorrubicina pegilada lipossomal em combinação com ecteinescidina 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
ATE499098T1 (de) * 2005-11-25 2011-03-15 Pharma Mar Sa Verwendung von parp-1-hemmern
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN109276719A (zh) * 2018-11-01 2019-01-29 中山万汉制药有限公司 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
WO1998052598A1 (en) * 1997-05-21 1998-11-26 Genentech, Inc. Novel administration of thrombopoietin
SK285669B6 (sk) * 1998-04-06 2007-06-07 The Board Of Trustees Of The University Of Illinois Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie
RU2225864C2 (ru) * 1998-05-11 2004-03-20 Фарма Мар, С.А. Метаболиты эктейнасцидина-743, фармацевтическая композиция на их основе и способы лечения
JP2000081438A (ja) * 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE495793T1 (de) * 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
MXPA03007989A (es) * 2001-03-06 2003-12-04 Bristol Myers Squibb Co Metodo y forma de dosificacion para tratamiento de tumores por administracion de tegafur, uracil, acido folinico, paclitaxel y carboplatin.
JP4391038B2 (ja) * 2001-05-10 2009-12-24 パナソニック株式会社 電気炊飯器
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
CA2583464A1 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
PT1827500E (pt) * 2004-10-26 2009-08-05 Pharma Mar Sa Doxorrubicina pegilada lipossomal em combinação com ecteinescidina 743
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
ATE499098T1 (de) * 2005-11-25 2011-03-15 Pharma Mar Sa Verwendung von parp-1-hemmern
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
HUP0400648A2 (hu) 2004-06-28
HK1060067A1 (en) 2004-07-30
EP1365808A2 (en) 2003-12-03
JP2004517056A (ja) 2004-06-10
AU2002212499B2 (en) 2006-11-02
CN1486193A (zh) 2004-03-31
MXPA03003975A (es) 2004-02-12
DE60143911D1 (de) 2011-03-03
PT1365808E (pt) 2011-04-08
NO329981B1 (no) 2011-01-31
EP1365808B1 (en) 2011-01-19
SK287901B6 (sk) 2012-03-02
WO2002036135A3 (en) 2003-04-10
BG107843A (bg) 2004-06-30
SK5492003A3 (en) 2004-03-02
NO20032027L (no) 2003-07-04
WO2002036135A2 (en) 2002-05-10
BR0115162A (pt) 2003-10-21
JP2009114212A (ja) 2009-05-28
AU1249902A (en) 2002-05-15
CN100374162C (zh) 2008-03-12
US20040108086A1 (en) 2004-06-10
CY1112361T1 (el) 2015-12-09
US20090324744A1 (en) 2009-12-31
DK1365808T3 (da) 2011-05-16
JP4391083B2 (ja) 2009-12-24
NZ525730A (en) 2004-12-24
US20120107417A1 (en) 2012-05-03
ATE495793T1 (de) 2011-02-15
KR20030048127A (ko) 2003-06-18
PL361389A1 (en) 2004-10-04
KR100718946B1 (ko) 2007-05-16
EA005564B1 (ru) 2005-04-28
NO20032027D0 (no) 2003-05-06
EA200300544A1 (ru) 2003-08-28
CA2428160C (en) 2009-10-13
HUP0400648A3 (en) 2012-09-28
CA2428160A1 (en) 2002-05-10
CZ20031327A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
IL155781A0 (en) Effective antitumor treatments
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
NZ544472A (en) Compounds and therapeutical use thereof
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
BRPI0518250A2 (pt) tratamentos anticÂncer
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
PL371741A1 (en) A combination treatment for acute myocardial infarction
IL159770A0 (en) Calcium salts with cytotoxic activity
MXPA04005269A (es) Uso de alcanoil-l-carnitina para el tratamiento de disfuncion erectil.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
GB0208129D0 (en) Method of treatment
IL157408A (en) Use of elemental calcium in the manufacture of a medicament to reduce prostate cancer risk
NZ516564A (en) Cancer therapy